| 2,814 | 407 | 280 |
| 下载次数 | 被引频次 | 阅读次数 |
<正>在1960年美国国家癌症研究所(National Cancer Institute,NCI)的Zubrod等[1]通过比较氮芥与噻替哌的疗效,首次提出了癌症化疗疗效评价标准的概念和方法[2]。1981年Cancer上正式发表了修订的世界卫生组织(world health organization,WHO)实体瘤疗效标准。经由欧洲癌症研究与治疗协会(european organization for research on treatment of cancer,EORTC)、NCI和加拿大国立癌症研究所(national cancer institute of canada,NCIC)进行修改和补充,于2000年公布了新的实体瘤疗效评价标准(response evaluation criteria in solid
Abstract：[1]Zubrod CG,Schneiderman SM,Frei E,et al.Appraisal of methods for the study of chemotherapy of cancer inman:comparative therapeutic trial of nitro genmustard and thiophosphamide[J].J Chronic Dis,1960,11:7-33.
[2]马建辉.重视实体瘤疗效评价标准的变革——RECIST概要[J].中华泌尿外科杂志,2006,27:77-79.
[3]Duffaud F,Therasse P.New guidelines to evaluate the response to treatment in solid tumors[J].Bull Cancer,2000,87:881-886.
[4]Choi H,Charnsangavej C,de Castro Faria S,et al.CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment:a quantitative analysis correlated with FDG PET findings[J].AJR Am J Roentgenal,2004,183:1619-1628.
[5]杨柳青,秦叔逵.GIST分子靶向药物疗效评价的新标准[J].临床肿瘤学杂志,2008,13:942-947.
[6]Miller AB,Hongstraten B,Staquet M,et al.Reporting results of cancer treatment[J].Cancer,1981,47:207-214.
[7]Bruix J,Sherman M,Llovet JM,et al.Clinical management of hepatocellular carcinoma.Conclusions of the Barcelona-2000EASL conference.European Association for the Study of the Liver[J].J Hepatol,2001,35:421-430.
[8]Stacchiotti S,Collini P,Messina A,et al.High grade soft-tissue sarcomas:tumor response assessment-pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria[J].Radiology,2009,251:447-456.
[9]Bruix J,Sherman M;American Association for the Study of Liver Diseases.Management of hepatocellular carcinoma:an update[J].Hepatology,2011,53:1020-1022.
[10]Lencioni R,Llovet JM.Modified RECIST(mRECIST)assessment for hepatocellular carcinoma[J].Sem Liver Dis,2010,30:52-60.
[11]Dai X,Schlemmer HP,Schmidt B,et al.Quantitative therapy response assessment by volumetric iodine-uptake measurement:initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib[J].Eur J Radiol,2013,82:327-334.
[12]Eisenhauer EA,Therasse P,Bogaerts J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1)[J].Eur J Cancer,2009,45:228-247
[13]杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4:85-90.
基本信息:
DOI：10.13455/j.cnki.cjcor.2015.09.40
中图分类号:R730.5
引用信息:
[1]丁婕,戴旭,孟宪运,等.实体瘤疗效评价标准的研究进展[J].中国肿瘤临床与康复,2015,22(09):1150-1152.DOI:10.13455/j.cnki.cjcor.2015.09.40.